Edition:
United States

Shanghai Pharmaceuticals Holding Co Ltd (601607.SS)

601607.SS on Shanghai Stock Exchange

21.87CNY
14 Feb 2018
Change (% chg)

¥0.16 (+0.74%)
Prev Close
¥21.71
Open
¥21.74
Day's High
¥22.03
Day's Low
¥21.70
Volume
3,759,347
Avg. Vol
12,999,734
52-wk High
¥29.25
52-wk Low
¥20.81

Chart for

About

Shanghai Pharmaceuticals Holding Co., Ltd. is a China-based company principally engaged in the manufacture and sales of pharmaceuticals. The Company's businesses include the research and registration, production, sales, distribution and retailing of pharmaceutical products, among others. Its products are applied in cardiovascula... (more)

Overall

Beta: 0.96
Market Cap(Mil.): ¥56,788.23
Shares Outstanding(Mil.): 2,842.09
Dividend: 0.36
Yield (%): 1.65

Financials

  Industry Sector
P/E (TTM): -- 20.91 17.28
EPS (TTM): -- -- --
ROI: -- 11.55 35.61
ROE: -- 13.54 17.17

Shanghai Pharmaceuticals plans $400 mln share sale to fund production

HONG KONG, Jan 19 Shanghai Pharmaceuticals Holding Co Ltd said on Friday it planned to sell HK$3.13 billion ($400 million) worth of new shares to fund the development of its manufacturing and distribution businesses.

Jan 18 2018

BRIEF-Shanghai Pharmaceuticals Holding To Place 153.2 Mln New H Shares At HK$20.43 Per H Share​

* ‍TO PLACE 153.2 MILLION NEW H SHARES AT HK$20.43 PER H SHARE​

Jan 18 2018

BRIEF-Shanghai Pharmaceuticals Holding units receive GMP certificate

* Says Changzhou-based pharmaceuticals unit received goods manufacture practice (GMP) certificate from Jiangsu Food and Drug Administration, for its products including acyclovir, ganciclovir and production line

Jan 10 2018

BRIEF-Shanghai Pharmaceuticals Holding unit receives GMP certificate

* Says its unit received goods manufacture practice (GMP) certificate from Shandong Food and Drug Administration, for its products including mixture, oral liquid, drops and bulk drug

Jan 04 2018

BRIEF-Shanghai Pharmaceuticals Holding Announces ‍CSRC's Approval On Issuance Of New Shares

* ANNOUNCES ‍CSRC'S APPROVAL ON ISSUANCE OF NEW 153.2 MILLION H SHARES AT VALUE OF RMB1 PER SHARE​ Source text for Eikon: Further company coverage:

Dec 29 2017

BRIEF-Shanghai Pharmaceuticals Gets Regulatory Approval To Issue Up To 153.2 Mln H-Shares

* SAYS IT GETS SECURITIES REGULATOR'S APPROVAL TO ISSUE UP TO 153.2 MILLION H-SHARES Source text in Chinese: http://bit.ly/2C81gx7 Further company coverage: (Reporting by Hong Kong newsroom)

Dec 29 2017

BRIEF-Shanghai Pharmaceuticals Holding To Transfer Entire Stake In Shanghai Huashi Asset Management

* ANNOUNCES ‍TRANSFER OF 100% EQUITY INTEREST IN SHANGHAI HUASHI ASSET MANAGEMENT CO TO A CONTROLLING SHAREHOLDER​

Dec 19 2017

BRIEF-Shanghai Pharmaceuticals Holding unit receives GMP certificate

* Says its wholly owned unit received goods manufacture practice (GMP) certificate from Shanghai Food and Drug Administration

Dec 11 2017

BRIEF-Shanghai Pharmaceuticals Holding unit receives GMP certificate

* Says its Shanghai-based unit received goods manufacture practice (GMP) certificate from Shanghai Food and Drug Administration

Dec 05 2017

BRIEF-Shanghai Pharmaceuticals Holding unit receives GMP certificate

* Says its wholly owned unit received goods manufacture practice (GMP) certificate from Shanghai Food and Drug Administration

Dec 03 2017

Earnings vs. Estimates